budesonide for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
PRINCIPLE ISRCTN86534580		RCT	budesonide	standard of care	COVID 19 outpatients	some concern	1073/1988	conclusif	demonstrated 21 % increase in clinical improvement,recovery (PE) with a moderate degree of certainty due to some concern in risk of bias
STOIC NCT04416399		RCT	budesonide	standard of care	COVID 19 outpatients	high	73/73	conclusif	demonstrated 84 % decrease in clinical deterioration (PE) but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis